Safety and immunogenicity of a novel oral hexavalent rotavirus vaccine：a phase I clinical trial-Reference-Cited by-同舟云学术

Safety and immunogenicity of a novel oral hexavalent rotavirus vaccine：a phase I clinical trial

Published:2021-02-05 Issue:7 Volume:17 Page:2311-2318
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Wu Zhi-Wei¹,Li Qing-Liang²,Zhou Hai-Song³,Duan Kai²,Gao Zhao¹,Zhang Xin-Jiang³,Jiang Zhi-Jun²,Hao Zhi-Yong³,Jin Fei¹,Bai Xuan²,Li Qi¹,Xu Ge-Lin²,Zhao Yu-Liang¹,Yang Xiao-Ming²

Affiliation:

1. Hebei Province Center for Disease Control and Prevention, Shijiazhuang, People’s Republic of China

2. Wuhan Institute of Biological Products Co., Ltd., Wuhan, People’s Republic of China

3. Zhengding County Center for Disease Control and Prevention, Zhengding, People’s Republic of China

Funder

sponsored and funded by Wuhan Institute of Biological Products Co., Ltd

Publisher

Informa UK Limited

Subject

Pharmacology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/21645515.2020.1861874

Reference34 articles.

1. Global, Regional, and National Estimates of Rotavirus Mortality in Children <5 Years of Age, 2000–2013

2. World Health Organization. Rotavirus vaccines. WHO Position Paper, February 1, 2013.

3. Hospital-based study of the economic burden associated with rotavirus diarrhea in eastern China

4. Rotavirus-specific and Overall Diarrhea Mortality in Chinese Children Younger than 5 Years

5. WHO. Meeting of the immunization strategic advisory group of experts. 2009 April;84(23):220–36.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Progress in research and development of preventive vaccines for children in China;Frontiers in Pediatrics;2024-07-03

2. Genotype analysis of rotaviruses isolated from children during a phase III clinical trial with the hexavalent rotavirus vaccine in China;Virologica Sinica;2023-12

3. Human rotavirus strains circulating among children in the capital of China (2018–2022)_ predominance of G9P[8] and emergence ofG8P[8];Heliyon;2023-08

4. Immunogenicity and safety of a new hexavalent rotavirus vaccine in Chinese infants: A randomized, double-blind, placebo-controlled phase 2 clinical trial;Human Vaccines & Immunotherapeutics;2023-08

5. Efficacy, safety and immunogenicity of hexavalent rotavirus vaccine in Chinese infants;Virologica Sinica;2022-10